3.0 PATIENT ELIGIBILITY AND STUDY ENTRY 
3.1 Eligibility 
Two groups of patients are eligible: 
- Group 1: those who received carboplatin, etoposide, melphalan, and local irradiation (CEM-LI, protocol 91LA6) or 
other marrow-ablative therapy followed by ABMT approximately 100 days previously, who usually do not have 
detectable disease but who are at significant risk for recurrence. 
- Group 2: those who have persistent or progressive disease. 
3.11 Genetically engineered neuroblastoma cells. The patient must have available either autologous or 
one locus matched (unrelated) neuroblastoma cells that are transfected with EFN-y vectors and that can be prepared in 
sufficient quantity for immunization according to RAC and FDA guidelines. 
3.12 Immune status. Absolute lymphocyte count at least 1500/mm^; T and B cell numbers, PHA response, 
within 3 SD of normal for age. 
3.13 Previous therapy. No exclusions. Patients must have fully recovered from the toxic effects of any prior 
therapy. At least 2 weeks should have elapsed since the last dose of chemotherapy (4 weeks in the case of 
nitrosourea containing therapy). 
3.14 Patients must have been less than 21 years of age when originally diagnosed to be treated on this protocol. 
3.15 Patients must have had histologic vOTfication of neuroblastoma 
3.16 Patients in Group 2 must have disease that is refractory to conventional therapy. 
3.17 Patients must have a performance status of 0 or 1 (Appendix L). 
3.18 Patients must have a life expectancy of ^ months. 
3.19 All patients must have: 
3.19.1 Adequate bone marrow fimction, defined as: 
Peripheral absolute neutrophil count (ANC) >l(XX)/mm^ 
Platelet count ^0,000/mm^ (may receive platelet transfusions) 
Hemoglobin ^8.0 gm/dl (may receive RBC transfusions) 
3.19.2 Adequate renal function defined as: 
Serum creatinine <1.5 x normal, or 
Creatinine clearance or radioisotope GFR >40 ml/min/m^ or >70 ml/min/1.73 m^ 
3.19.3 Adequate liver function defmed as: 
Total bilirubin <1.5 X normal, and 
SCOT (AST) or SGPT (ALT) <2.5 x normal. 
3.194 Central nervous system function defined as: 
Patients with seizure disorder may be enrolled if seizures are well controlled by anticonvulsants. 
CNS toxicity <grade 2. 
3.21 All patients and/or their legal guardians must sign a written informed consent 
3.22 All instiUJtional, FDA, NCI, and RAC requirements for human studies must be met. 
3.2 Study Entry Patients will be entered on study by telephoning (213) 669-4565 between 8:30 a.m. and 
5:00 p.m. Monday through Friday, including holidays. The information requested on the Telephone Study Entry 
Form must be provided at the time of this telephone call. The dose level will be assigned by Drs. Seeger or 
Villablanca at the time of study entry. 
[ 100 ] 
Recombinant DNA Research, Volume 19 
